CD274 and non-small cell lung carcinoma: For instance, in the KEYNOTE-189 trial,36 improved overall survival and objective response rates were found in pembrolizumab plus pemetrexed-platinum regimen compared to placebo plus pemetrexed-platinum regimen in patients with metastatic NSCLC, regardless of PD-L1 expression level.